In another market-study report, the New York-based strategic management consulting firm Datamonitor predicted a significant decline in the global antihypertensive market by the year 2010.
In another market-study report, the New York-based strategic management consulting firm Datamonitor predicted a significant decline in the global antihypertensive market by the year 2010.
Patents for popular calcium channel blockers and ACE inhibitors, which presently account for 40% and 35% of the $24.7 million antihypertensive market, will expire by the beginning of the next century. Increased competition from generics and wider acceptance of newer therapies (such as angiotensin II receptor antagonists) will loosen the familiar products' dominant hold on the market.
Values for popular calcium channel blockers, such as Bayer's Adalat and Hoescht Marion Roussel's Cardizem, for example, may decline drastically, according to the report. Sales for Adalat, currently worth $1.16 billion, may drop to $82 million by 2010; sales of Cardizem, worth $1.79 billion, may dip to $91 million.
Sales of Pfizer's newer Norvasc, on the other hand, will initially grow to $1.9 billion by 2005. But by 2010, when its patent expires, sales will fall to $495 million.
ACE inhibitors will suffer a similar fate. Sales of Merck's Vasotec, currently valued at $2.5 billion, will fall to $514 million by 2005. Bristol-Myers Squibb's Capoten and Zeneca's Zestril also appear to be positioned for a drop in sales, according to the report.
Angiotensin II receptor antagonists, which entered the antihypertensive market in 1995, will benefit from the declining market strength of ACE inhibitors and calcium channel blockers.
Sales in this new category of antihypertensives may reach $3 billion by 2005. For example, as profits from Merck's Vasotec ACE inhibitor fall, profits from the company's angiotensin II receptor antagonist Cozaar/Hyzaar will rise to $1.7 billion by 2005.
Sales from this new drug class alone may make up for the overall decrease in the antihypertensive market, the report concluded. PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
Recent Developments in Pharmaceutical Validation
November 1st 2024Explore the latest pharmaceutical validation developments with industry experts from Barry-Wehmiller Design Group, Kneat Solutions, and No Deviation. You’ll gain valuable data-driven insights and discover emerging trends from the State of Validation 2024 industry report that are shaping the validation landscape.